Technology and Science

What We Build

Our platform is designed to identify, match, and deliver the right phage for the right infection. Using artificial intelligence, we scan an ever-growing library of phage candidates and match them to bacterial targets based on genomic, behavioral, and environmental profiles. Every step is built to ensure safety, scalability, and ecological compatibility.

Our Products

We are advancing this mission through two proprietary products: QUINT and QUINTx.

QUINT

QUINT works by analyzing bacterial and phage genomic sequences to predict which phages are most likely to infect a specific bacterial strain. It applies machine learning models trained on known phage–host interactions, detecting genetic signatures and compatibility markers. This enables QUINT to prioritize the most promising phage candidates for laboratory validation, significantly reducing the trial-and-error process.

QUINTx

When no existing phage is predicted to work, QUINTx extends the process using generative algorithms. It designs novel phage sequences by recombining functional genomic elements and simulating their interaction with the target bacteria. QUINTx then evaluates these synthetic candidates against biological constraints to ensure viability before moving to lab testing. This enables exploration beyond natural phage diversity to address resistant or novel bacterial infections.

Both products are powered by NVIDIA DGX Cloud infrastructure, which integrates with Evo2, the most comprehensive foundational genomic model to date. This enables our platform to process complex bacterial data and respond with unmatched precision and adaptability.

The Engine Behind Our Platform

Bacterial Identification

The process begins when a laboratory or infectious disease team cultures a sample and provides the DNA-sequenced pathogen from a patient, animal, or agricultural source.

Phage Discovery and Matching

The sequenced pathogen is analyzed against our proprietary phage databases using QUINT and QUINTx. If a match is found, QUINTx will identify the candidate phages that are flagged as suitable for therapy. If no match is found, QUINTx will use our AI solution to suggest the top candidate phages for Partner Collaboration to begin development.

Clinical Engagement

The results are presented to the infectious disease team. Once the physician, veterinarian, or agricultural professional places an order, the process advances for the preparation of therapy.

Partner Collaboration

Through our specialized lab and manufacturing partners, patient, animal, or crop specimens are received for confirmatory testing. Phages are then manufactured, optimized, and prepared as a therapeutic formulation.

Testing and Validation

Our partners perform validation to ensure the safety, potency, and specificity of the phage therapy before it is released.

Formulation and Delivery

The final therapy is packaged and delivered directly to the treating clinician, veterinarian, or agricultural specialist.

Targeted Action and Natural Resolution

Phage therapy selectively eliminates harmful bacteria, supporting the natural recovery process in patients, animals, or crops.

Cross-Domain Applications

This process supports clinical medicine with personalized therapies for resistant infections, veterinary medicine with precision treatment for livestock and companion animals, and agriculture with sustainable protection against bacterial pathogens in crops.

Good things : )

Frequently Asked Question

What is Page Therapy and how does it work?

Phage Therapy uses naturally occurring viruses, called bacteriophages, to find and destroy harmful bacteria. Unlike antibiotics, phages are precise; they target only the “bad” bacteria and leave the rest of the body’s good bacteria untouched.

How does Page Therapy save time and cost?

Phage Therapy saves time and costs by precisely targeting harmful bacteria, reducing the need for trial-and-error treatments, and minimizing hospital stays. This focused approach reduces complications and resistance, resulting in faster recovery and significant long-term savings.

Is Page Therapy suitable for small clinics?

Phage Therapy is ideal for small clinics because it can be delivered through targeted treatments without requiring extensive infrastructure. With AI support, clinicians can quickly match the right phage, making it practical, affordable, and accessible for smaller care settings.